Xanomeline NEW
| Price | $50 | $85 | $168 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-11 |
Product Details
| Product Name: Xanomeline | CAS No.: 131986-45-3 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2025/06/11 |
Product Introduction
Bioactivity
| Name | Xanomeline |
| Description | Xanomeline (LY-246708) is a functionally selective M1/M4 activator used in the study of neurological disorders such as schizophrenia and has shown promising treatment in preclinical trials. Xanomeline is well absorbed orally, crosses the blood-brain barrier and undergoes extensive liver metabolism with at least six metabolites. |
| In vitro | In binding studies pre-incubating cells for one hour with 1 μM xanomeline, but not carbachol, reduced N-[3H]methylscopolamine saturation binding affinity but not maximal receptor density in cells [1]. |
| In vivo | Animal studies have shown the role of M4 and M1 receptors in modulating psychotic and behavioral disturbances and correction of negative and/or cognitive symptoms, respectively. The time to reach maximum plasma concentration (Tmax) for xanomeline is 2.5 hours, and maximum plasma concentration following xanomeline 150mg is 13.8ng/mL. Xanomeline is widely distributed, including to the CNS in animal studies, and the majority of the drug is excreted via the kidneys within 24 hours of administration[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.5 mg/mL (15.99 mM), Sonication is recommended. |
| Keywords | Xanomeline | mAChR M4 | mAChR M1 | LY246708 | LY 246708 |
| Inhibitors Related | Adiphenine hydrochloride | Nanofin | Forskolin | Pilocarpine Hydrochloride | Clozapine N-Oxide | Pilocarpine nitrate | Urethane | Ribavirin | D-Menthol | Amitriptyline hydrochloride | Choline chloride | Propoxur |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2025-02-14 | |
| $0.00/5KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2024-11-12 | |
| $1.10/1g |
VIP5Y
|
Dideu Industries Group Limited
|
2021-05-28 | |
| $9.80/1.8KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-13 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2025-02-14 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY